27th September 2019
They will pitch in the finals during the 2-3 December EIT Health Summit in Paris
A vaccine for cancer, gene therapy for respiratory disease and an epilepsy drug that targets the disease instead of the symptoms were among the innovations winning the competitive pitch contest at EIT Health’s European Health Catapult Biotech semi-finals in Delft, The Netherlands on 24-26 September 2019.
The European Health Catapult Biotech semi-final, organised by TU Delft and hosted by Biotech Campus Delft and DSM, involved 13 exceptional biotech start-ups, who participated in a two-day intensive training aimed at strengthening their value proposition pitching skills. After their training, the start-ups pitched before a jury for the competition, which coincided with the EIT Health Investor Forum. All of the competing start-ups, who were seeking a total of €112 million in future investment, also had an opportunity to network and establish further connections with investors and health industry representatives.
“The EHC-competition is a unique chance for start-ups to introduce themselves for the European health and healtcare sectors and to meet with intersting research institutes, companies and investors,”
Bart Haex, Business Creation Manager at EIT Health Belgium-Netherlands.
EIT Health supported Sleepiz AG secures EUROSTAR grant
To help sufferers of sleep apnea
EIT Health Bootcamp selects 11 female-led start-ups
Connecting women-led teams to mentors and investors
EIT Health selecting three Supervisory Board members
Independent members sought; apply by 23 May